Ipsen (IPN) H1 2024 earnings summary

Executive summary

• Total sales grew by 9.5% in H1 2024 to €1,659m, with a core operating margin of 32.4% and free cash flow of €394m.

• Achieved key U.S. launches and FDA approvals for Onivyde (first-line pancreatic cancer) and Iqirvo (second-line PBC); further CHMP opinions pending.

• Pipeline advanced with ex-U.S. licensing of tovorafenib for pediatric oncology and expanded collaborations for Cabometyx.

• Upgraded FY 2024 guidance for total sales growth and core operating margin, reflecting strong commercial execution.

• Robust launches and positive physician feedback for Onivyde and Iqirvo supported by early payer coverage.

Financial highlights

• Total sales reached €1,659m, up 9.5% at constant exchange rates; core operating income rose 2.8% to €538m.

• IFRS consolidated net profit increased 19.1% to €232m; EBITDA up 2.6% to €583m.

• Free cash flow grew 5.9% to €394m; closing net debt reduced to €6.8m from €272m in H1 2023.

• Gross margin declined by 1.6 points due to sales mix and higher royalties; R&D costs rose to 19.5% of sales.

• SG&A costs grew 4%, with improved efficiency post-acquisitions; SG&A ratio to sales improved by 1.4 points to 34.6%.

Outlook and guidance

• Upgraded 2024 guidance: total sales growth expected above 7% at constant exchange rates (previously above 6%).

• Core operating margin anticipated above 30% of sales, with lower profitability in H2 due to increased investment and seasonality.

• Guidance assumes accelerated Somatuline erosion from generics, offset by higher contributions from new launches.

• Currency headwinds expected to impact total sales by around 1% for the full year.